FLU SV mRNA

**FLU SV mRNA** is an investigational mRNA-based vaccine candidate targeting influenza, likely encoding surface antigens such as hemagglutinin from specific strains (SV denoting surface viral proteins). It utilizes messenger RNA technology to instruct host cells to produce influenza antigens, eliciting both humoral and cellular immune responses against seasonal or pandemic flu strains. Developed as part of advancing mRNA platforms post-COVID vaccines, it aims for rapid manufacturing and potentially broader protection; specific developer, strain details (e.g., H1N1 or SV-specific), and exact formulation remain unconfirmed in available data, distinguishing it from quadrivalent candidates like Moderna's mRNA-1010 or Pfizer's PF-07976016.[2][3]